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Abstract
Objectives
Both maternal HIV infection and antiretroviral therapy are associated with adverse birth out-
comes. The role of antenatal nutrient supplements with regard to adverse birth outcomes in
HIV infected women exposed to antiretroviral therapy is not well known. We assessed the
association between HIV and birth outcomes and explored whether antenatal lipid-based
nutrient supplements (LNS) modulated this association.
Methods
We analysed a nested cohort of pregnant Malawian women who received daily LNS, multi-
ple micronutrients (MMN) or iron and folic acid (IFA). Birth weight, length-for-age z-score
(LAZ) and weight-for-age z-score (WAZ) were analysed as continuous outcomes and pro-
portion of stunting and small-for-gestational age (SGA) as dichotomous outcomes.
Results
134 HIV infected (46 LNS, 39 MMN, 49 IFA) and 833 HIV uninfected (271 LNS, 287 MMN,
275 IFA) women were included. Maternal HIV infection was associated with a lower mean
birth weight (-129g (-209, -48), P = 0.002); LAZ (-0.34 (-0.54, -0.13), P = 0.002) and WAZ
(-0.21 (-0.40, -0.02), P = 0.041) and a higher risk of stunting (RR (95% confidence interval),
1.87 (1.24, 2.83), P = 0.003) and SGA (1.66 (1.21, 2.26), P = 0.001) in the newborn. If the
women received LNS, HIV was not associated with LAZ (mean difference (95%); -0.02
(-0.35, 0.31), P = 0.918) or newborn stunting (RR (95% CI), 0.84 (0.34, 2.03), P = 0.691).
However HIV tended to be associated with LAZ if the women received MMN (-0.42 (-0.80,
-0.03), P = 0.053); and was significantly associated with LAZ if the women received IFA
(-0.52 (-0.89, -0.14), P = 0.021) and with newborn stunting if they received MMN (2.40 (1.15,
4.98), P = 0.029) or IFA (2.40 (1.26, 4.59), P = 0.024).
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Conclusions
Further research to investigate the impact of LNS on various aspects of foetal growth in HIV
infected women is warranted.
Introduction
Global estimates indicate that 17.8 million women aged>15 years were living with human
immunodeficiency virus (HIV) in 2016 [1]. Following the rapid scale-up of antiretroviral ther-
apy (ART) [2] there has been a considerable reduction in vertical transmission and HIV asso-
ciated maternal and child mortality [1]. However, maternal HIV continues to be associated
with adverse birth outcomes such as preterm birth (PTB) and low birth weight (LBW) even in
the context of ART use [3]. Indeed, different aspects of maternal ART including timing of ini-
tiation of therapy (pre-conception vs post-conception) or type of antiretroviral regimen have
been reported to influence the risk of adverse birth outcomes in HIV infected women [4,5].
Mechanisms for PTB or foetal growth restriction (FGR) in HIV infected women are not
well understood. Maternal anaemia, low body-mass-index (BMI), low mid upper arm circum-
ference (MUAC) and low gestational weight gain (GWG) have been identified as risk factors
for PTB and FGR in HIV infected women [6–8]. A possible pathway for PTB and FGR is
increased oxidative stress levels that have been observed more frequently in HIV infected indi-
viduals [9] and in placentas from HIV infected women [10]. Oxidative stress has been linked
to PTB and FGR [11,12]. Considering this knowledge, antenatal provision of dietary supple-
ments that may improve maternal nutritional status or reduce oxidative stress may prevent the
occurrence of these adverse birth outcomes.
In this study, we evaluated the association between maternal HIV infection and the rate of
gestational weight gain (GWG), inadequate GWG and a wide range of birth outcomes (dura-
tion of pregnancy, birth weight, length-for age z-score (LAZ), weight-for-age z-score (WAZ),
weight-for-length z-score (WLZ), head circumference-for-age z-score (HCZ), PTB, LBW,
stunting, underweight, wasting and small-for-gestational age (SGA)). We further examined
whether the association between HIV and these pregnancy outcomes would be influenced by
lipid-based nutrient supplements (LNS). LNS contain several micronutrients, macrominerals
and macronutrients such as protein and essential fatty acids [13]. Alpha linolenic acid, an n-3
fatty acid, has been shown to reduce oxidative stress in rats [14].
Materials and methods
We conducted a secondary cohort analysis of data collected from pregnant women who partic-
ipated in the iLiNS-DYAD-Malawi trial (Trial Registration www.clinicaltrials.gov, Identifier:
NCT01239693). This was a randomized controlled nutrient intervention trial that evaluated
the impact of LNS on pregnancy outcomes. The analysis we are reporting now was defined a
priori in the iLiNS-DYAD-Malawi study protocol. Ethical approval for the trial was obtained
from the College of Medicine Research and Ethics Committee, University of Malawi and the
Ethics Committee of Pirkanmaa Hospital District, Finland. Written informed consent was
sought from all study participants prior to study participation.
Details of the main iLiNS-DYAD-M trial and the main study results have been described
elsewhere [15]. Briefly, we recruited pregnant women who attended antenatal clinics at four
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health facilities in Mangochi district, a predominantly rural district in South Eastern Malawi.
Provision of LNS was not associated with improved birth outcomes [15].
As part of the main trial, participating women received daily oral iron and folic acid (IFA)
tablet, multiple micronutrients (MMN) tablet or a sachet of small-quantity LNS throughout
pregnancy. The description of the study supplements [15] and the rationale for the formula-
tion of LNS have been reported previously [13]. Briefly, the IFA tablets contained 60 mg of
iron (standard dose) whereas the MMN tablets and the LNS sachet contained 20 mg iron each;
all 3 supplements contained 400 mcg of folic acid. In addition to IFA the MMN and LNS sup-
plements contained 16 other micronutrients. The LNS also contained 4 macrominerals (phos-
phorus, calcium, potassium and magnesium) and essential fatty acids (linoleic acid and alpha-
linolenic acid) and provided 118 kcal per day.
For this report, we used data that were collected at enrolment (baseline and exposure data)
and at two scheduled clinic visits at 32 and 36 gestation weeks (maternal weight), and as soon
as possible after birth and at 1–6 weeks postpartum (newborn anthropometry).
The outcome variables of interest were rate of GWG (g/ week), pregnancy duration (gesta-
tion weeks), birth weight (grams), LAZ, WAZ, WLZ, HCZ, inadequate GWG (GWG below
the lower limit of the recommended weight gain according to the Institute of Medicine’s
(IOM) recommendations [16]), PTB (delivery occurring <37 gestation weeks), LBW (birth
weight <2500g), stunting (LAZ<-2 at birth) underweight (WAZ<-2 at birth), wasting
(WLZ<-2), small head circumference (HCZ <-2 at birth) and SGA (birth weight below the
10th centile of the Intergrowth Standards). Maternal HIV infection at enrolment was the main
exposure of interest.
Based on prior axiomatic knowledge, the following baseline variables were defined a priori
as potential confounders for the relationship between HIV and adverse pregnancy outcomes:
maternal age (years), maternal education (number completed years in school), proxy score for
socio-economic status (SES) estimated based on household assets adjusted score system [17],
BMI (maternal weight (kg) / maternal height (cm)2), MUAC (measured in cm to one decimal
place), maternal anaemia at enrolment (haemoglobin <110g/l) and maternal Plasmodium fal-
ciparum infection at enrolment. The type of nutrient supplement received in the iLiNS--
DYAD-M trial was considered a potential effect modifier of the relationship between HIV
infection and study outcomes.
We determined maternal HIV status on venous blood using the Alere Determine HIV-1/2
Rapid Test (Alere Medical Co) and confirmed positive results using Uni-Gold Rapid Test
(Trinity Biotech Co., Wicklow). Use of ART was variable among the HIV infected women
who participated in the study. A small proportion of the HIV infected women who already
knew their status were using ART prior to conception. Newly diagnosed women or those who
were not yet on ART were referred to the health facility’s ART clinic for further management
of HIV infection.
We analysed our data using Stata 12.1 (StataCorp, College Station, USA). We restricted our
analyses to women who had live singleton births only. Specifically, we excluded women who
had no HIV test result, twin gestation, miscarriage, stillbirth, unusual data (gestational age
>42 weeks), or incomplete outcome data. The rate of GWG was calculated as the difference
between maternal weight measured at the 32/36-wk visit minus maternal weight measured at
baseline divided by the number of weeks between these 2 measurements. We defined inade-
quate GWG as weekly GWG below the lower limit of the Institute of Medicine (IOM) recom-
mended rate for the second and third trimesters (454, 364, 227, 182 g/week for underweight,
normal-weight, overweight and obese women respectively) [16].
Since the IOM recommendations are based on pre-pregnancy BMI, we estimated maternal
BMI before pregnancy by first determining the best transformation of maternal BMI at
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enrolment that achieved a normal distribution and then regressed the transformed BMI with
age, age squared, and age cubed to generate predicted and residual values. We then inspected
the regression curve to determine the earliest gestation age before the confidence interval
expanded, with the assumption that weight gain before that point was minimal. Next, we cal-
culated the predicted mean BMI at 13.7 weeks, and this was used as a proxy for pre-pregnancy
BMI.
We compared continuous measurements and categorical outcomes between HIV infected
and HIV uninfected participants, and between women included or excluded from the analysis.
We used linear regression to estimate the coefficient or difference in means. We estimated the
risk ratio for the comparison of dichotomous outcomes at a single time point using log bino-
mial regression models or Poisson regression models in case the algorithm failed to converge
in the estimation.
To control for possible confounding, we adjusted for covariates that were identified a priori
as being potentially associated with both HIV infection and FGR. We assessed heterogeneity
of effects by stratifying HIV versus No-HIV comparisons by intervention group. We corrected
for multiple testing using the false discovery method [18]. Because maternal HIV status was
not listed as one of the main potential effect modifiers (hypothesis-driven) in the iLiNS--
DYAD-M statistical analysis plan, the stratified analyses were exploratory.
Results
Out of the 1391 women enrolled into the iLiNS-DYAD-M study, 967 were eligible for analysis.
We performed our outcome analyses on this cohort of 134 HIV infected and 833 HIV unin-
fected pregnant women. Women excluded from the outcome analyses (n = 424) due to missing
HIV test results, twin gestation, miscarriage, stillbirth, dropout or incomplete outcome data
(Fig 1) tended to be younger (23.9 versus 25.4 y), to be wealthier (0.15 versus -0.05), to be pri-
migravid (31.8% versus 17.5%), to have a higher BMI (22.5 versus 22.0 kg/m2) and to be anae-
mic (24.4% versus 19.0%) but were otherwise similar to women included in the analyses in
terms of the other baseline characteristics (S1 Table).
Overall, the rate of attrition was similar between the HIV negative and HIV positive
women (27.6 vs 26.8%, P = 0.801). The rates of miscarriage or stillbirth did not differ according
to maternal HIV infection (P = 0.259; P = 0.341, respectively). Baseline characteristics of HIV
Fig 1. Flow chart of participants included in the analysis.
https://doi.org/10.1371/journal.pone.0215760.g001
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infected, and uninfected women were similar in terms of their height, BMI, education attain-
ment and gestational age at enrolment (P>0.05). However, HIV infected participants tended
to be older, to be wealthier, to have a lower haemoglobin level and were less likely to be primi-
gravid (Table 1).
HIV infected women did not differ significantly from HIV uninfected women in terms of
pregnancy duration or newborn WLZ or HCZ, but they had a slower rate of GWG (273 vs 297
g/week, P = 0.004) and they delivered babies who were lighter (2882 versus 2987g, P = 0.002)
and shorter (LAZ -1.28 versus -0.99, P = 0.002 (Table 2). The proportions of infants with PTB,
LBW, stunting and SGA were significantly higher among HIV infected women as compared
to HIV uninfected women. However, there were no statistically significant associations
between maternal HIV status and proportion of women with inadequate GWG or proportion
of infants with wasting, underweight or small head size (Table 3).
The numbers randomised to receive LNS, MMN and IFA were 46, 39 and 49, and 271, 287
and 275 in the HIV infected and HIV uninfected women respectively. Stratified analyses for
continuous birth outcomes that were significantly associated with HIV infection in the main
analysis showed that the values for birth weight, LAZ and WAZ for HIV infected women who
received LNS were consistently closer to those of uninfected women regardless of the type of
the intervention received by the uninfected women. Comparisons between HIV infected and
uninfected women indicated that for all outcomes the values were mostly lower among
infected versus non-infected women in each of the intervention groups, though these differ-
ences were statistically significant only for birth weight in the MMN group and LAZ in the
IFA group (Table 4).
Like the findings from the stratified analyses of continuous outcomes, the risk of preterm
birth, and stunting in HIV infected women who received LNS was closer to the risk observed
in HIV uninfected women regardless of type of supplement received by the uninfected
women. Maternal HIV was not associated with LBW or SGA in any of the three intervention
groups. In contrast, the risk of PTB was significantly higher among infected versus uninfected
women only among those in the MMN group and not in the IFA or LNS groups. The risk of
Table 1. Baseline characteristics of the women included in the analysis, by HIV status.
Characteristic No HIV HIV P value
Number of participants 833 134
Mean (SD) maternal age, years 24.9 (6.1) 28.8 (5.2) <0.001
Mean (SD) maternal education, completed years at school 4.0 (3.4) 3.9 (3.6) 0.755
Mean (SD) household assets score -0.09 (0.92) 0.13 (1.10) 0.021
Mean (SD) gestational age at enrolment, weeks 16.8 (2.1) 16.6 (2.2) 0.075
Primigravid, % 19.8 3.0 <0.001
Mean (SD) height, cm 156.1 (5.6) 156.2 (5.9) 0.849
Mean (SD) MUAC, cm 26.3 (2.6) 26.6 (2.3) 0.105
Wasting (MUAC<22 cm), % 7.2 4.5 0.246
Mean (SD) BMI, kg/m2 22.0 (2.8) 22.3 (2.5) 0.243
Low BMI (< 18.5 kg/m2), % 5.7 4.5 0.354
Mean (SD) blood hemoglobin concentration, g/l 112 (16.1) 108 (17.6) 0.002
Anaemia (Hb < 100 g/l), % 18.3 23.9 0.125
P. falciparum infection (RDT), % 22.3 21.6 0.873
MUAC, mid-upper arm circumference; BMI, body-mass-index; RDT, rapid diagnostic testing
P-values were obtained from t-test (comparison of means) or Chi square test (comparison of proportions).
https://doi.org/10.1371/journal.pone.0215760.t001
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newborn stunting was significantly higher among infected versus uninfected women in the
IFA and MMN groups but similar between infected and uninfected women who received LNS
(Table 5).
Out of the 134 HIV infected participants, 38 (28.4%) received ART during pregnancy (20
started ART prior to joining the study and 18 after enrolment into the study) and 10 (7.5%)
started ART after delivery; for 30 (22.3%) women it was unknown when they started therapy
and for 43 (32.1%) treatment status was unknown. ART status was not associated with type of
nutrient supplement received in the main trial (P = 0.702). Because ART use during pregnancy
may increase the risk of adverse birth outcomes [19], we conducted a sensitivity analysis in
which we excluded all HIV positive women who were on ART (Tables 6 and 7).
The associations between maternal HIV and GWG, birth weight, LAZ, WAZ, preterm
birth, LBW, newborn stunting and SGA persisted (P<0.05) after excluding those who were on
ART. Notably, the associations between HIV and LBW, newborn stunting and SGA were
Table 2. Continuous pregnancy outcomes by HIV infection statusa.
Outcome No HIV
(N = 833)
HIV
(N = 134)
Unadjusted difference in means (95%
CI)b
P-valueb Adjusted difference in means (95%
CI)b
P-valueb
Gestational weight gain rate, g/
week
297 (102) 273 (108) -25 (-43, -6) 0.010 -28 (-47, -9) 0.004
Duration of pregnancy, weeks 39.4 (1.60) 39.3 (1.84) -0.11 (-0.41, 0.19) 0.470 -0.11 (-0.42, 0.20) 0.493
Birth weight, g 2987 (425) 2882 (447) -105 (-183, -27) 0.009 -129 (-209, -48) 0.002
Length-for-age z-score -0.99 (1.10) -1.27 (1.16) -0.29 (-0.49, -0.08) 0.006 -0.34 (-0.54, -0.13) 0.002
Weight-for-age z-score -0.55 (1.01) -0.69 (1.07) -0.14 (-0.33, 0.04) 0.135 -0.21 (-0.40, -0.02) 0.041
Weight-for-length z-score 0.10 (1.13) 0.21 (1.07) 0.10 (-0.11, 0.31) 0.330 0.05 (-0.17, 0.26) 0.663
Head circumference z-score -0.15 (1.08) -0.25 (1.20) -0.10 (-0.30, 0.10) 0.337 -0.13 (-0.34, 0.08) 0.223
a Values are means (standard deviations) unless otherwise indicated
bDifferences in means and P-values were estimated using linear regression models
Models were adjusted for the following maternal factors: age, education, proxy score for socio-economic status (SES), body-mass-index, mid-upper arm circumference,
anaemia at enrolment and Plasmodium falciparum infection at enrolment.
https://doi.org/10.1371/journal.pone.0215760.t002
Table 3. Adverse pregnancy outcomes by HIV infection statusa.
Outcomes No HIV
(N = 833)
HIV
(N = 134)
Unadjusted Risk ratio
(95% CI)b
P-
valueb
Adjusted Risk Ratio
(95% CI) b
P-
valueb
Inadequate gestational weight gainc 597 (72.2) 99 (73.9) 1.02 (0.83, 1.27) 0.831 1.06 (0.85. 1.33) 0.594
Preterm birth (<37 gestation weeks) 47 (5.6) 16 (11.9) 2.12 (1.24, 3.62) 0.006 1.99 (1.14, 3.46) 0.015
Low birth weight (<2500g) 98 (11.8) 26 (19.4) 1.65 (1.11, 2.44) 0.012 1.81 (1.20, 2.73) 0.005
Newborn stunting (LAZ<-2) 124 (14.9) 33 (24.6) 1.65 (1.18, 2.32) 0.003 1.87 (1.24, 2.83) 0.003
Newborn underweight (WAZ<2) 56 (6.7) 13 (9.7) 1.44 (0.81, 2.56) 0.211 1.56 (0.86, 2.83) 0.144
Newborn wasting (WLZ<-2) 31 (3.7) 2 (1.5) 0.40 (0.10, 1.66) 0.207 0.45 (0.10, 1.93) 0.282
Newborn small head size (HCZ<-2) 31 (3.7) 9 (6.7) 1.80 (0.88, 3.71) 0.108 1.81 (0.86, 3.80) 0.119
Small-for-gestational-age (birth weight below 10th percentile of
birth weight for age (Intergrowth Standards)
235 (28.2) 55 (41.0) 1.45 (1.16, 1.83) 0.001 1.66 (1.21, 2.26) 0.001
aValues are n (%) unless otherwise indicated
bRisk ratio and P-values were estimated using log binomial models or Poisson regression models
cBelow the lower cutoff of the Institute of Medicine’s recommended range [16]
All models were adjusted for age, education, proxy score for socio-economic status (SES), body-mass-index, mid-upper arm circumference, anaemia at enrolment and
Plasmodium falciparum infection at enrolment.
https://doi.org/10.1371/journal.pone.0215760.t003
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attenuated after excluding those who were on ART whereas the association between maternal
HIV and PTB strengthened. We did not collect information on the exact ARV drugs received
by the individual HIV positive women participating in the study. However, in general the
ARV regimen for pregnant women in Malawi at the time of the study included stavudine,
lamivudine, nevirapine, zidovudine, efavirenz, tenofovir and lopinavir/ritonavir. Since private
ART care was rare in the area it is likely that most of the women were on this regimen. There
was one case of spina bifida identified in an infant born to an HIV positive woman.
Because previous studies conducted in the pre-ART era showed that HIV was associated
with a smaller head circumference [20], we explored whether the mean head circumference
differed according to maternal ART use in our study. After adjusting for possible confounders,
our results showed that there was no difference in the mean head circumference of infants
born to HIV positive mothers who were receiving ART when compared to ART naïve HIV
positive mothers (Mean difference HCZ (95% CI), 0.23 (-0.23, 0.70); P = 0.332).
Since there was a considerable loss to follow up, we performed an intention to treat analysis
where all individuals excluded from the analysis because of miscarriages, stillbirth or incom-
plete/improbable data were assumed to have had a poor outcome. Those with twin gestation
or missing HIV results were not included in this analysis because twin gestation itself is a risk
factor for adverse outcomes and HIV status was required as the independent variable. Out of
the 1322 participants included in the sensitivity analysis, 645 infants (including 336 who were
defined as being SGA) were considered to have FGR. Maternal HIV infection was associated
with FGR (1.27 (1.01, 1.59, P = 0.039).
Table 4. Continuous pregnancy outcomes by HIV status, stratified by intervention groupa.
Outcome No HIV
Mean (95% CI)
HIV
Mean (95% CI)
Adjusted difference in means (95% CI)b P-valueb PFDRc
Gestational weight gain rate, (g/week)
LNS 298 (105) 278 (105) -20 (-53, 13) 0.231 0.231
MMN 298 (101) 263 (113) -42 (-76, -7) 0.017 0.051
IFA 297 (101) 276 (107) -29 (-62, 4) 0.082 0.123
Mean (SD) birth weight, g
LNS 2996 (420) 2988 (478) -143 (-125, 153) 0.841 0.841
MMN 3004 (426) 2822 (457) -192 (-339, -45 0.011 0.033
IFA 2962 (430) 2826 (394) -151 (-289, -12) 0.033 0.051
Mean (SD) length-for-age z-score
LNS -0.95 (1.04) -0.98 (0.91) -0.02 (-0.35, 0.31) 0.918 0.918
MMN -0.96 (1.08) -1.38 (1.33) -0.42 (-0.80, to -0.03) 0.035 0.053
IFA -1.05 (1.16) -1.47 (1.19) -0.52 (-0.89, -0.14) 0.007 0.021
Mean (SD) weight-for-age z-score
LNS -0.51 (0.96) -0.37 (0.95) 0.10 (-0.21, 0.41) 0.516 0.516
MMN -0.53 (1.01) -0.92 (1.10)) -0.40 (-0.76, -0.05) 0.027 0.081
IFA -0.60 (1.05) -0.83 (1.08) -0.31 (-0.65, 0.023) 0. 067 0.101
LNS, lipid-based nutrient supplements; MMN, multiple micronutrient supplements; IFA, iron folic acid; and PFDR, positive false discovery rate. Women with no HIV:
LNS (N = 271); MMN (N = 287) and IFA (N = 275). Women with HIV: LNS(N = 46), MMN (39), IFA (49).
a Values are means (standard deviations) unless otherwise indicated
bDifferences in means and P-values were estimated using linear regression models
cP value adjusted for multiple testing using false discovery rate method [18]
All models were adjusted for age, education, proxy score for socio-economic status (SES), body-mass-index, mid-upper arm circumference, anaemia at enrolment and
Plasmodium falciparum infection at enrolment
https://doi.org/10.1371/journal.pone.0215760.t004
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Table 5. Adjusted dichotomous pregnancy outcomes by HIV status, stratified by intervention groupa.
Outcome No HIV
N (%)
HIV
N (%)
Risk Ratio (95%
CI)b
P-valueb PFDRc
Preterm birth (<37 gestation weeks)
LNS 13 (4.8) 2 (4.4) 0.96 (0.20, 4.51) 0.958 0.958
MMN 15 (5.2) 7 (17.5) 4.79 (1.84, 12.5) 0.001 0.003
IFA 19 (6.9) 7 (14.3) 1.83 (0.68, 4.94) 0.235 0.235
Low birth weight (<2500g)
LNS 31
(11.4)
8 (17.4) 1.74 (0.75, 4.03) 0.193 0.243
MMN 34
(11.9)
7 (17.5) 1.66 (0.71, 3.87) 0.243 0.243
IFA 33
(12.0)
11
(22.5)
1.94 (0.91, 4.96) 0.088 0.243
Newborn stunting (LAZ<-2)
LNS 43
(15.9)
6 (13.0) 0.84 (0.34, 2.03) 0.691 0.691
MMN 38
(13.2)
11
(27.5)
2.40 (1.15, 4.98) 0.019 0.029
IFA 43
(15.6)
16
(32.7)
2.40 (1.26, 4.59) 0.008 0.024
Small-for-gestational-age (birth weight below 10th percentile of birth weight for age (Intergrowth
Standards)
LNS 81
(29.9)
15
(32.6)
1.13 (0.64, 2.02) 0.688 0.688
MMN 75
(26.1)
16
(40.0)
1.65 (0.91, 2.97) 0.098 0.147
IFA 79
(28.7)
25
(51.0)
2.12 (1.29, 3.47) 0.003 0.099
LNS, lipid-based nutrient supplements; MMN, multiple micronutrient supplements; IFA; iron folic acid; and PFDR, positive false discovery rate. Women with no HIV:
LNS (N = 271); MMN (N = 287) and IFA (N = 275). Women with HIV: LNS(N = 46), MMN (39), IFA (49).
aValues are n (%) unless otherwise indicated
bRisk ratio and P-values were estimated using log binomial models or Poisson regression models
cP value adjusted for multiple testing using false discovery rate method [18]
All models were adjusted for age, education, proxy score for socio-economic status (SES), body-mass-index, mid-upper arm circumference, anaemia at enrolment and
Plasmodium falciparum infection at enrolment
https://doi.org/10.1371/journal.pone.0215760.t005
Table 6. Sensitivity analysis: HIV and continuous pregnancy outcomes after excluding HIV positive women who were on antiretroviral therapya.
Outcome No HIV
(N = 833)
HIV
(N = 134)
Unadjusted difference in means (95%
CI)b
P-valueb Adjusted difference in means (95%
CI)b
P-valueb
Gestational weight gain rate, g/
week
297 (102) 263 (101) -34 (-56, -13) 0.002 -36 (-57, -14) 0.001
Duration of pregnancy, weeks 39.4 (1.60) 39.1 (1.76) -0.33 (-0.67, 0.01) 0.061 -0.34 (-0.69, 0.00) 0.052
Birth weight, g 2987 (425) 2890 (446) -98 (-188, -7) 0.034 -123 (-213, -32) 0.008
Length-for-age z-score -0.99 (1.10) -1.25 (1.092) -0.27 (-0.50, 0.04) 0.024 -0.33 (-0.56, -0.10) 0.005
Weight-for-age z-score -0.55 (1.01) -0.71 (1.02) -0.16 (-0.38, 0.05) 0.131 -0.27 (-0.51, -0.02) 0.036
Weight-for-length z-score 0.10 (1.13) 0.12 (1.07) 0.02 (-0.22, 0.26) 0.868 -0.01 (-0.25, 0.24) 0.957
Head circumference z-score -0.15 (1.08) -0.30 (1.11) -0.15 (-0.37, 0.08) 0.213 -0.17 (-0.41, 0.06) 0.143
a Values are means (standard deviations) unless otherwise indicated
bDifferences in means and P-values were estimated using linear regression models
https://doi.org/10.1371/journal.pone.0215760.t006
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Discussion
We investigated the association between maternal HIV and pregnancy outcomes, and whether
this association differed across nutrient intervention groups in a cohort of women participat-
ing in a nutrient supplementation trial in southern rural Malawi. The study findings show that
maternal HIV status was inversely associated with weekly GWG, birth weight, LAZ, and WAZ
and positively associated with PTB, LBW, stunting and being born SGA. HIV infected women
who received LNS tended to have values of birth size or risk of adverse outcomes similar to
that of HIV uninfected women regardless of the type of supplement received by the uninfected
women. The association between HIV infection and PTB and newborn stunting differed
according to the type of dietary supplementation received during pregnancy. Maternal HIV
was not associated with PTB if the mothers received LNS or IFA; or newborn stunting if the
mothers received LNS.
The main weakness of our study was that there was significant loss to follow up whereby
only 70% of participants were eligible for inclusion in the analysis. Additionally, there were dif-
ferences in some of the baseline characteristics between those who were included and those
excluded in the analysis. The differences in socioeconomic status score, age and BMI were
unlikely to have affected our results because socioeconomic status score was not associated
with birth weight in this population and the differences in age and BMI were probably too
small to be clinically meaningful. However, considering that the proportions of primigravidity
and anaemia were much higher among the excluded women and that they are both associated
with foetal growth faltering, we may have underestimated the impact of HIV on birth size.
However, after controlling for characteristics that differed between the included and excluded
participants, our adjusted results did not change for the most part. Further, the rate of attrition
did not differ by HIV infection and intention-to-treat-analysis supported the findings that
HIV was associated with FGR.
A limitation of these analyses was that the main iLiNS-DYAD-Malawi trial was not pow-
ered for the stratified analyses and the study may have lacked sufficient power to detect differ-
ences in the incidence of relatively uncommon dichotomous outcomes such as PTB and LBW.
Therefore, failure to observe a significant association between HIV and PTB or LBW among
women who received IFA or MMN (for LBW only) needs to be interpreted with caution.
Table 7. Sensitivity analysis: Adjusted adverse pregnancy outcomes by HIV infection status after excluding HIV positive women who were on antiretroviral
therapya.
Outcomes No HIV
(N = 833)
HIV
(N = 134)
Unadjusted Risk ratiob
(95% CI)
P-
valueb
Risk Ratio
(95% CI) b
P-
valueb
Inadequate gestational weight gainc 597 (72.2) 74 (77.1) 1.07 (0.84, 1.36) 0.595 1.11 (0.87, 1.42) 0.399
Preterm birth (<37 gestation weeks) 47 (5.6) 1313.58) 2.40 (1.35, 4.27) 0.003 2.34 (1.30, 4.19 0.004
Low birth weight (<2500g) 98 (11.8) 17 (17.7) 1.50 (0.94, 2.41) 0.088 1.62 (1.00,
2.63)
0.049
Newborn stunting (LAZ<-2) 124 (14.9) 24 (25.0) 1.68 (1.15, 2.46) 0.008 1.93 (1.23, 3.05 0.004
Newborn underweight (WAZ<2) 56 (6.7) 8 (8.3) 1.24(0.61 2.52) 0.553 1.31 (0.63, 2.71) 0.465
Newborn wasting (WLZ<-2) 31 (3.7) 2 (2.08) 0.56 (0.14, 2.30) 0.421 0.56 (0.13, 2.40) 0.438
Newborn small head size (HCZ<-2) 31 (3.7) 5 (5.2) 1.40 (0.56, 3.51) 0.474 1.37 (0.53, 3.50) 0.514
Small-for-gestational-age (birth weight below 10th percentile of birth
weight for age (Intergrowth Standards)
235 (28.2) 39 (40.6) 1.44 (1.10, 1.88) 0.007 1.62 (1.14,
1.30)
0.007
aValues are n (%) unless otherwise indicated
bRisk ratio and P-values were estimated using log binomial models or Poisson regression models
https://doi.org/10.1371/journal.pone.0215760.t007
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Even though we could determine ART status in less than half of the women, we were able
to show that maternal ART status was evenly distributed in the nutrient supplement groups.
Analysis restricted to ART naïve HIV positive women showed weaker associations between
HIV and birth size but a stronger association with PTB. This concurs with observations from
the Tanzania study where ART use was associated with higher rates of LBW and SGA but
lower or similar rates of PTB [19]
It was not surprising to observe a significantly lower rate of GWG among the HIV infected
women. Pregnancy itself is associated with increased energy requirements [21]. In addition,
the increased energy requirements [22] and reduced dietary intake, probably due mainly to
reduced appetite [23], that are associated with HIV infection may lead to slower weight gain
especially in resource-limited settings where the food intake may not be sufficient to meet the
daily needs. Provision of LNS was not associated with improvement in the rate of GWG
among HIV infected or HIV uninfected women. This is similar to findings among healthy
women in Ghana [24] but not among healthy women in Bangladesh where antenatal LNS
improved the rate of GWG, though only among multiparous women� 25 years [25].
Similar to findings from a recent meta-analysis, our study showed that maternal HIV infec-
tion was associated with the occurrence of PTB and LBW [3]. Like in our study, women
included in the meta-analysis had variable ART use and treatment with ARV drugs did not
appear to change the relationship between maternal HIV infection and PTB or LBW [3]. We
identified one previous study that compared newborn stunting and underweight between HIV
exposed and HIV unexposed babies in Tanzania [26]. The overall rate of stunting was higher
in Tanzania than in our Malawi study population. In contrast, the overall rate of underweight
was almost twice as high in Malawi. These differences may be due to differences in background
characteristics between the two study populations. Similar to this study, maternal HIV was
associated with newborn stunting but not with newborn underweight. The failure to observe
an association with newborn underweight in the Malawi and Tanzania studies may have been
due to insufficient study power to detect a difference considering that the rates of underweight
were very low in these countries.
Maternal HIV infection was not associated with newborn head circumference in our study.
This is similar to reported observations in Tanzania [26]. However, earlier studies conducted
in the pre-ART era found that maternal HIV infection was associated with head circumference
[20]. Maternal ART may protect against the adverse effects of HIV on foetal head growth by
preventing the progression of HIV disease. Even though maternal ART use was not associated
with newborn head circumference in this study, it is possible that widespread availability of
ART allows HIV infected women to access treatment before progression of HIV disease to
advanced stages which have been associated with adverse outcomes earlier [27,28].
The lack of association between maternal HIV and pregnancy outcomes was not limited to
women who received LNS but was also observed for some outcomes among those who
received either MMN or IFA. Nevertheless, there is a consistent pattern whereby values of
birth size or the risk of adverse birth outcomes among HIV infected women who received LNS
are closer to those of HIV negative women irrespective of type of supplement received than
they are to those of HIV positive women who received either MMN or IFA. This observation
suggests that LNS may be protective against the negative effects of maternal HIV infection on
foetal growth. HIV infection is associated with lower maternal weight [29], anaemia [30], oxi-
dative stress [9,31] and micronutrient deficiencies [32,33]. The first three have been shown to
be associated with poor foetal growth [11,34,35], and presumed reversal of micronutrient defi-
ciencies by MMN supplementation during pregnancy has resulted in larger birth size in multi-
ple clinical trials [36]. LNS may prevent HIV associated adverse birth outcomes by reducing
the risk of one or more of these four factors.
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With regard to maternal weight, women with inadequate GWG according to IOM guide-
lines were more likely to have SGA or LBW babies in the USA [37] and Taiwan [38]. In sub-
group analysis of this study, prevalence of inadequate GWG among HIV infected women was
similar between those who received LNS and those who received IFA. This therefore makes it
unlikely that LNS improved foetal growth among infected women through increases in GWG.
Antenatal iron use is associated with reduced risk of maternal anaemia [39]. Receiving LNS
(with 20 mg iron) in the iLiNS-DYAD-Malawi trial was associated with a higher risk of mater-
nal anaemia at 36 gestation weeks, compared to IFA with 60 mg of iron [40]. This therefore
indicates that LNS could not have prevented FGR by reducing the risk of maternal anaemia in
this study.
It is unlikely that improvement in maternal micronutrient status due to LNS explains our
findings because the MMN group received the same daily dose of 18 micronutrients as the
LNS group, yet the risk of stunting or SGA was lower in the LNS group than in the MMN
group. This suggests that other factors such as the macrominerals or essential fatty acids that
were present in LNS and not in the MMN may have been responsible for preventing FGR in
HIV infected women.
There is insufficient evidence to conclusively demonstrate that antenatal supplementation
with macrominerals improves foetal growth. A meta-analysis that reviewed 15 randomised
controlled trials showed that antenatal supplementation with calcium was associated with a
modest increase in birth weight but no impact on intrauterine growth restriction was observed
[41]. There is little research on the association between phosphorus or potassium supplemen-
tation and foetal growth. On the other hand, a Cochrane review showed no impact of antenatal
magnesium on the occurrence of SGA [42]. More research on the role of macrominerals with
regard to foetal growth is needed to increase our understanding of whether prenatal supple-
mentation with such nutrients is beneficial.
While the LNS differed in protein and energy content compared to the IFA, the difference
was probably not large enough to affect foetal growth in a population that likely does not meet
the estimated average requirement of nutrients as observed in a study that was conducted
close to our study area [43]. The level of protein (2.6 g) in the LNS was much less than the esti-
mated average requirement of protein in early and late gestation (1.2g/kg and 1.54g /kg respec-
tively) [44] and the extra 118 kcal of energy was unlikely to meet the dietary deficits of HIV
pregnant women [45]. A recent observational study in Australia showed that maternal intake
of alpha linolenic acid was lowest in the group that had SGA babies compared to those who
had appropriate- or large-for-gestational-age babies [46] suggesting improved foetal growth in
women who had a higher intake of alpha linolenic acid. In our study, however, improved foetal
growth was observed only in HIV infected women who received LNS and not in the unin-
fected women who received LNS. It is probable that in our study population essential fatty
acids may have prevented FGR in HIV infected women through other mechanisms as
explained below.
It is possible that the LNS reduced the occurrence of HIV associated adverse birth outcomes
through the effects of alpha linolenic acid. Oxidative stress is associated with FGR through oxi-
dative damage and inflammation to placental tissue which leads to placental insufficiency [11].
An increase in markers of oxidative stress has been reported in individuals with HIV infection
when compared to healthy subjects [9]. In the main iLiNS-DYAD-M trial, LNS provision
increased the plasma levels of alpha linolenic acid, a precursor of docosahexanoic acid and
eicosapentanoic acid. These long chain n-3 polyunsaturated fatty acids are associated with
antioxidant and anti-inflammatory activities [47,48]. Thus, LNS may have decreased oxidative
stress and inflammation, thereby reducing FGR among HIV positive women.
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These data indicate the potential role antenatal LNS may have in reducing HIV-associated
adverse birth outcomes in the era of widespread use of ART. In Tanzania, antenatal supple-
mentation with multivitamins (B1, B2, B6, niacin, B12, C, E and folic acid) reduced the risk of
LBW, PTB and SGA among women who had no access to ART [49]. Our study also demon-
strates that HIV infected pregnant women who may not be eligible for nutritional supplements
according to guidelines of some countries, e.g. do not qualify as undernourished based on
MUAC, may have improved birth outcomes if they receive antenatal small-quantity LNS. Only
4.5% of the HIV infected women in our study would have qualified for nutritional supple-
ments according to the current guidelines for nutritional support in Malawi which recom-
mend nutritional supplements only to pregnant women with moderate undernutrition
(MUAC: 190–219 mm) or severe undernutrition (MUAC<190 mm) [50].
Conclusions
Further research to investigate the impact of LNS on various aspects of foetal growth in HIV
infected women is warranted.
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